%0 Journal Article
%T 儿童恶性血液病合并医院获得性肺炎的抗生素疗效分析<br>Analysis of Antibiotic Efficacy in Children with Tumor of the Hematopoietic and Lymphoid Tissues Complicated with Hospital Acquired Pneumonia
%A 常瑜
%A 林荣军
%J Advances in Clinical Medicine
%P 2133-2138
%@ 2161-8720
%D 2020
%I Hans Publishing
%R 10.12677/ACM.2020.109921
%X <div style=\"text-align:justify;\">
	目的：探讨美罗培南和哌拉西林/他唑巴坦在治疗恶性血液病患儿合并医院获得性肺炎抗生素的疗效，并对其进行安全性分析，为临床用药提供参考。方法：采用回顾性调查分析自2017年1月至2019年9月期间共60例恶性血液病患儿合并医院获得性肺炎的临床资料，根据所用抗生素种类不同分为观察组和对照组。观察组应用美罗培南，共34例；对照组应用哌拉西林/他唑巴坦，共26例；观察两种抗生素的临床疗效及不良反应。结果：两组患儿治疗总有效率观察组为75.3%、对照组为53.8%，两组差异无统计学意义。结论：美罗培南及哌拉西林/他唑巴坦治疗恶性血液病合并医院获得性肺炎在疗效上没有明显差异，均在临床治疗中不良反应较少。<br />
Objective: To evaluate the efficacy and safety of Meropenem and Piperacillin Tazobactam in the treatment of hospital acquired pneumonia in children with tumor of the hematopoietic and lymphoid tissues. Methods: A retrospective study was conducted to analyze the clinical data of 60 children with tumor of the hematopoietic and lymphoid tissues pneumonia from January 2017 to September 2019. The patients were divided into observation group and control group according to the type of antibiotics used. In the observation group, 34 cases were treated with Meropenem; in the control group, 26 cases were treated with Piperacillin/tazobactam. Results: The total effective rate of the two groups was 75.3% in the observation group and 53.8% in the control group. Conclusion: There is no significant difference between Meropenem and Piperacillin Tazobactam in the treatment of tumor of the hematopoietic and lymphoid tissues associated with hospital acquired pneumonia and there are fewer adverse reactions in clinical treatment.
</div>
%K 儿童，恶性血液病，医院获得性肺炎，抗生素<br>Children
%K Tumor of the Hematopoietic and Lymphoid Tissues
%K Hospital Acquired Pneumonia
%K Antibiotics
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=37800